← All China Pharma Holdings, INC filings

China Pharma Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
CPHI
China Pharma Holdings, INC
10-K: China Pharma Holdings Reports Fiscal Year 2024 Results Amidst Challenging Market Conditions
China Pharma Holdings reports a decline in revenue for fiscal year 2024 due to increased competition and regulatory changes in the Chinese pharmaceutical market.
AMEX
CPHI
China Pharma Holdings, INC
10-K: China Pharma Holdings Inks Technology Transfer Deals, Reports Mixed Financial Results in 2023
China Pharma Holdings acquired new drug patents for chronic obstructive pulmonary disease and psoriasis while facing revenue declines and a net loss in 2023.